News
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
Lindus Therapeutics, a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board of directors as a non-executive director.
Announcing our $18m Series A led by investors Creandum and with participation from Peter Thiel
The funding comes from Spotify-backer Creandum, with participation from PayPal co-founder Peter Thiel and returning investors firstminute, Seedcamp, Hambro Perks, Amino Collective, Page One Ventures and Calm/Storm. Additional investment has been provided by angel investors including Nadav Rosenberg, Kaysan Nikkhah, Trevor Martin, Soraya Darabi, Andrej Steinberg, Tom Krüger and Mithi Thaya.
Lindus Health Named Fierce CRO Award Winner in the Outstanding Patient Recruitment and Retention Category
Lindus Health wins the 2025 Fierce CRO Award for Outstanding Patient Recruitment and Retention, highlighting the innovative use of our PIC technique.
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
Lindus Therapeutics, a next-generation drug development company advancing a portfolio of in-licensed assets, has announced the appointment of Dr. Gillian Cannon to its board of directors as a non-executive director.
.png)
Dr. Paul Billings Joins Lindus Health's Scientific Advisory Board
Lindus Health has announced the appointment of Dr. Paul Billings to its Scientific Advisory Board, strengthening its expertise in diagnostic and genomic medicine. A recognized leader in diagnostics with decades of experience across industry and clinical research, Dr. Billings will help guide Lindus Health’s strategy for designing and executing high-quality diagnostic clinical trials, supporting faster, more reliable paths from diagnostic innovation to patient impact.
Lindus Health Named Rising Star in the 2025 Deloitte Technology Fast 50
This prestigious recognition reflects Lindus’ ongoing commitment to developing adaptive, innovative technology that fixes the broken Contract Research Organization (CRO) model through its all-in-one solution.
Lindus Health Partners with Yendou to Streamline Site Engagement and Accelerate Clinical Trial Feasibility
This collaboration strengthens Lindus’ ability to deliver robust end-to-end clinical trials through one unified solution.
Lindus Health Named Fierce CRO Award Winner in the Outstanding Patient Recruitment and Retention Category
Lindus Health wins the 2025 Fierce CRO Award for Outstanding Patient Recruitment and Retention, highlighting the innovative use of our PIC technique.
Lindus Health Named a 2025 Fierce CRO Award Finalist in the Outstanding Patient Recruitment and Retention Category
Lindus Health has been shortlisted for the Fierce CRO Awards in the Outstanding Patient Recruitment and Retention Category
Lindus Health co-founder Meri Beckwith named on PM360's 2025 Elite 100
Meri Beckwith makes the PM360 Elite 100 for 2025.
Lindus Health Awarded Funding From ARIA to Build Safe and Reliable AI for Clinical Trial Design
Lindus Health has been awarded funding from ARIA to develop a groundbreaking AI-assisted clinical trial design system with built-in safety guarantees, in collaboration with the University of Oxford, aiming to make trials faster, more reliable, and scientifically rigorous.